Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 770 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07702838Recruiting
Immunotherapy and carbon ion radiation for advanced cervical cancer
This trial tests a new treatment that combines immunotherapy (drugs that help your immune system fight cancer) with carbon ion radiation (a precise type of radiation) for people with locally advanced cervical cancer that hasn't spread to other organs. The goal is to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT04918186RecruitingPhase 2
Immunotherapy for platinum-resistant ovarian, with tumor testing
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Chicago, IllinoisAges 18 years+ - NCT04016129RecruitingPhase 1/Phase 2
CAR-T therapy for certain B-cell blood cancers
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
Shenzhen, GuangdongAges 6 months–75 years - NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT04157127RecruitingPhase 1
Pancreatic cancer vaccine with chemotherapy before/around surgery
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Houston, TexasAges 18 years+ - NCT04163562RecruitingPhase 1/Phase 2
Oral peanut treatment trial for people with peanut allergy
This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.
Pamplona, NavarreAges 12–65 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT04272658Recruiting
Whole-body PET/CT scan during immunotherapy for melanoma
This trial studies how a whole-body PET/CT scan (using a radioactive sugar called FDG) can better track metastatic melanoma in people receiving immune therapy. It may help doctors understand tumor response to medications like nivolumab or pembrolizumab.
Brest, FinistereAges 18 years+ - NCT04278222RecruitingPhase 2
Anlotinib plus immunotherapy for advanced stomach cancer
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
ShanghaiAges 18 years+ - NCT04300062Recruiting
Rebiopsy of lung cancer after treatment no longer works
This trial studies patients with lung cancer whose disease has continued to grow despite immunotherapy. It involves taking a new tissue sample (a rebiopsy) to help doctors understand what changed during treatment and guide next steps.
Boulogne-BillancourtAges 18 years+ - NCT04324125Recruiting
Chemo plus immune therapy for HER2-positive advanced lung cancer
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Changsha, HunanAges 18 years+ - NCT04375384RecruitingPhase 2
Cetuximab after immunotherapy for head and neck cancer
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT04400539RecruitingPhase 2
Nivolumab plus 5-ALA light treatment for pleural mesothelioma
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
LilleAges 18 years+ - NCT04433221RecruitingPhase 1/Phase 2
Combination immunotherapy for sarcoma patients
This trial tests a combination of immune cells targeting sarcoma tumors. It is for people with advanced or recurrent sarcoma who have not responded well to standard treatments.
Shenzhen, GuangdongAges 1–75 - NCT04470024RecruitingPhase 1
Testing a vaccine plus immunotherapy for recurrent head and neck cancer
This early-phase (Phase 1b) study tests a vaccine designed to train the immune system to fight head and neck squamous cell carcinoma, plus standard immunotherapy. It may help some people by boosting the body’s anti-cancer immune response, but it mainly focuses on safety and finding the best approach.
Portland, OregonAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04543071RecruitingPhase 2
Second-line-like immunotherapy and chemo for metastatic pancreatic cancer
This Phase 2 trial studies a combination of immunotherapy, a blood-vessel/immune signal blocker, and chemotherapy for people with metastatic pancreatic adenocarcinoma. It may help shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT04544774Recruiting
Nasal allergen test to start and track allergy shots
This study uses a nasal allergen “provocation” test to help decide how to start and monitor allergy immunotherapy (allergy shots or drops). It may help doctors better track whether the treatment is working for people with allergic rhinitis.
Leuven, Vlaam BrabantAges 18–60 - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT04576429Recruiting
Tracking immune changes in melanoma patients on immunotherapy
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
Boulogne-BillancourtAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT04605146Recruiting
Telemonitoring to manage side effects from immunotherapy
This trial tests whether using home digital monitoring (telemonitoring) can help people with melanoma, lung, or kidney (renal) cancer manage side effects while on immunotherapy. It may help catch side effects earlier and support you during treatment with nivolumab plus ipilimumab or nivolumab alone.
BronAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 770 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.